Prostate Cancer Clinical Trial

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Summary

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

View Full Description

Full Description

Primary Objective: To evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Exploratory Objective:

Correlation of 68Ga PSMA 11 uptake and Gleason score at biopsy
Correlation of 68Ga RM2 and Gleason score at biopsy

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Suspected prostate cancer
Planned prostate biopsy
Able to provide written consent
Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria:

Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
Metallic implants (contraindicated for MRI)

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

14

Study ID:

NCT03809078

Recruitment Status:

Completed

Sponsor:

Andrei Iagaru

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Stanford California, 94305, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

14

Study ID:

NCT03809078

Recruitment Status:

Completed

Sponsor:


Andrei Iagaru

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.